Table 1. Characteristics of serogroup 19 isolates (n=36) obtained in the Czech Republic in 2014.
| Isolates | Serotype | Source | MIC (µg ml−1) | ATB resistance genes | CC | ST | Allelic profile | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | PEN | CTX | TET | ERY | CLI | CHL | SXT | aroE | gdh | gki | recP | spi | xpt | ddl | PMEN clone | ||||||
| 24 679 | 19A | Blood | 70 | 0.008 | 0.016 | 16.0 | >4.0 | 4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | Netherland15B-37/ST199 |
| 26 584 | 19A | Blood | 60 | 0.008 | 0.016 | 16.0 | >4.0 | >4.0 | 4.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 270 | 19A | CSF | 36 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416† | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 374 | 19A | Ear | 3 | 0.016 | 0.016 | >16.0 | >4.0 | 4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 389 | 19A | Ear | 3 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 417 | 19A | Blood | 64 | 0.016 | 0.016 | 16.0 | >4.0 | 4.0 | 4.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 491 | 19A | Ear | 3 | <0.004 | 0.016 | <0.125 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM* | 199 | 416† | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 630 | 19A | Blood | 68 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 775 | 19A | Ear | Unknown | 0.008 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 776 | 19A | Ear | Unknown | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 806 | 19A | Ear | 0 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 844 | 19A | Sputum | 62 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 854 | 19A | Ear | 3 | 0.016 | 0.03 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 27 897 | 19A | Nose | 6 | 0.016 | <0.004 | >16.0 | >4.0 | >4.0 | 2.0 | 0.5 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 28 206 | 19A | Blood | 73 | 0.008 | 0.03 | <0.125 | >4.0 | 2.0 | 2.0 | 0.5 | ermB, tetM* | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 28 240 | 19A | Ear | 0 | 0.008 | 0.03 | 16.0 | >4.0 | >4.0 | 2.0 | 0.5 | ermB, tetM | 199 | 416 | 1 | 13 | 14 | 4 | 17 | 51 | 14 | |
| 24 417 | 19A | Blood | 48 | 0.125 | 0.06 | <0.125 | 0.06 | 0.06 | 2.0 | 0.25 | 199 | 1756 | 8 | 20 | 14 | 4 | 17 | 4 | 14 | ||
| 25 138 | 19A | Blood | 71 | 0.008 | 0.03 | >16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 199 | 11 198 | 1 | 13 | 14 | 4 | 199 | 51 | 14 | |
| 25 137 | 19F | Blood | 57 | 8.0 | 4.0 | 16.0 | >4.0 | >4.0 | 0.5 | >4.0 | ermB, mefA, tetM | 320 | 271† | 4 | 16 | 19 | 15 | 6 | 20 | 26 | Taiwan19F-14/ST236 |
| 27 722 | 19A | Sputum | 67 | 2.0 | 1.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 24 238 | 19F | CSF | 73 | 4.0 | 2.0 | 8.0 | >4.0 | >4.0 | 2.0 | >4.0 | ermB, mefA, tetM | 320 | 1464† | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 24 633 | 19F | Sputum | 56 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 4.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 24 870 | 19F | Sputum | 65 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 24 993 | 19F | Sputum | 62 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 4.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 27 721 | 19F | Sputum | 60 | 2.0 | 1.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 27 723 | 19F | Sputum | 61 | 2.0 | 1.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 27 992 | 19F | Blood | 67 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 28 205 | 19F | Sputum | 73 | 4.0 | 2.0 | 16.0 | >4.0 | >4.0 | 2.0 | >4.0 | ermB, mefA, tetM | 320 | 1464 | 4 | 16 | 19 | 15 | 6 | 20 | 106 | |
| 24 493 | 19A | Blood | 21 | 0.25 | 0.25 | 16.0 | >4.0 | >4.0 | 2.0 | 0.125 | ermB, tetM | 230 | 230 | 12 | 19 | 2 | 17 | 6 | 22 | 14 | Denmark14-32/ST230 |
| 28 258 | 19A | Sputum | 69 | 0.5 | 0.125 | 16.0 | >4.0 | 0.5 | 2.0 | 0.125 | ermB, tetM | 230 | 230 | 12 | 19 | 2 | 17 | 6 | 22 | 14 | |
| 27 314 | 19A | Blood | 61 | 2.0 | 1.0 | 16.0 | >4.0 | 0.125 | 2.0 | 1.0 | ermB, tetM | 230 | 276 | 2 | 19 | 2 | 17 | 6 | 22 | 14 | |
| 25 833 | 19A | Blood | 60 | 0.5 | 0.25 | >16.0 | 0.06 | 0.125 | 2.0 | >4.0 | 230 | 2013 | 12 | 19 | 36 | 17 | 6 | 20 | 14 | ||
| 27 227 | 19A | Ear | 3 | 0.016 | 0.016 | >16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 193 | 3863 | 8 | 10 | 211 | 16 | 1 | 26 | 1 | Greece21-30/ST193 |
| 29 469 | 19A | Blood | 4 | 0.016 | 0.016 | 16.0 | >4.0 | >4.0 | 2.0 | 0.25 | ermB, tetM | 193 | 3863 | 8 | 10 | 211 | 16 | 1 | 26 | 1 | |
| 28 087 | 19F | Blood | 79 | 0.125 | 0.06 | 16.0 | 4.0 | >4.0 | 4.0 | 0.5 | ermB, tetM | 177 | 179 | 7 | 14 | 40 | 12 | 1 | 1 | 14 | Portugal19F-21/ST177 |
| 27 102 | 19A | Ear | 5 | <0.004 | 0.008 | >16.0 | >4.0 | 0.125 | 16.0 | 4.0 | ermB, tetM | 66 | 11 197 | 1 | 5 | 41 | 5 | 10 | 616 | 8 | |
PEN, penicilin; CTX, cefotaxime; TET, tetracycline; ERY, erytromycin; CLI, clindamycin; CHL, chloramphenicol; SXT, trimethoprim/sulfamethoxazole; CC, clonal complex; ST, sequence type; PMEN, Pneumococcal Molecular Epidemiology Network.
New sequence types are shown in bold.
*Isolates were found to be phenotypically susceptible due to the deletion of a 26-bp-long segment (from nucleotide position 16 298 to 16323) of the tetM gene.
†Isolates included in the whole-genome sequencing.